

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of ~~preventing or~~ reducing a T cell-mediated immune response in an individual, the method comprising:

selecting an individual diagnosed as having ~~or as being at risk of acquiring~~ a condition characterized by an excessive or unwanted T cell-mediated immune response; and

administering to the individual a composition comprising an effective amount of an antibody or antigen-binding fragment thereof that specifically ~~compound that~~ binds to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of a T cell, wherein the binding of the antibody or antigen-binding fragment thereof ~~compound~~ to PSGL-1 on the surface of the T cell induces a signal transduction pathway that results in the death of the T cell, thereby ~~preventing or~~ reducing a T cell-mediated immune response in the individual.

2. (Cancelled)

3. (Currently Amended) The method of claim 1, wherein the antibody or antigen-binding fragment thereof ~~compound~~ is a monoclonal antibody that specifically binds to PSGL-1.

4. (Currently Amended) The method of claim 3, further comprising administering an antibody agent that binds to the monoclonal antibody and induces the cross-linking of a plurality of PSGL-1 antigens on the surface of the T cell.

5. (Cancelled)

6. (Original) The method of claim 1, comprising selecting an individual diagnosed as having an autoimmune disease.

7. (Withdrawn) The method of claim 1, comprising selecting an individual that has received or is expected to receive an allogeneic or xenogeneic transplant.

8. (Withdrawn) The method of claim 1, comprising selecting an individual diagnosed as having an allergic disease.

9. (Withdrawn) The method of claim 1, comprising selecting an individual diagnosed as having a T cell cancer.

10. (Original) The method of claim 1, wherein the T cell is an activated T cell.

11. (Currently Amended) The method of claim 1, wherein the T cell is a CD4⁺ ~~CD4⁺~~ T cell.

12. (Currently Amended) The method of claim 1, wherein the T cell is a CD8⁺ ~~CD8⁺~~ T cell.

13. (Currently Amended) The method of claim 1, wherein the method comprises:
detecting the number of T cells in a first biological sample taken from the individual before the administration of the composition compound; and
comparing the number of T cells detected in the first biological sample results with the number of T cells in a second biological sample taken from the individual after the administration of the composition compound.

14-16. (Cancelled)

17. (Currently Amended) A method of inducing the death of a T cell or a natural killer (NK) cell, the method comprising:

providing a T cell or NK cell expressing PSGL-1 on its cell surface; and
contacting the T cell or NK cell with a an effective amount of an antibody or antigen-binding fragment thereof that specifically ~~compound~~ that binds to PSGL-1 on the surface of the T cell or NK cell, wherein the binding of the antibody or antigen-binding fragment thereof ~~compound~~ to PSGL-1 on the surface of the T cell or NK cell induces a signal transduction pathway that results in the death of the T cell or NK cell.

18. (Cancelled)

19. (Currently Amended) The method of claim 17, wherein the antibody or antigen-binding fragment thereof ~~compound~~ is a monoclonal antibody that specifically binds to PSGL-1.

20. (Currently Amended) The method of claim 19, further comprising contacting the monoclonal antibody with an antibody agent that binds to the monoclonal antibody and induces the cross-linking of a plurality of PSGL-1 antigens on the surface of the T cell or NK cell.

21. (Cancelled)

22. (Original) The method of claim 17, wherein the cell is an activated T cell.

23. (Currently Amended) The method of claim 17, wherein the cell is a CD4⁺ ~~CD4⁺~~ T cell.

24. (Currently Amended) The method of claim 17, wherein the cell is a CD8⁺ ~~CD8⁺~~ T cell.

25. (Currently Amended) The method of claim 17, wherein the method comprises assessing the viability of the T cell or NK cell after the contacting with the antibody or antigen-binding fragment thereof compound.

26-37. (Cancelled)